PRKG1 and Parkinson disease: Furthermore, in a variety of either toxin-induced or genetic PD models as well as in iPSC, treatment with terazosin, a PGK agonist, increased brain ATP and dopamine levels and restored motor function, providing support for the therapeutic approach of enhancing PGK and glycolytic activity in the treatment of PD (Cai et al., 2019).